Trial Profile
A Multicenter, Placebo-Controlled, Single Dose Study in Acute Episodic and Chronic Cluster Headache to Evaluate the Safety and Efficacy of SOM230 Subcutaneous (s.c.)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2020
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary)
- Indications Cluster headache
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 14 Feb 2019 Status changed from completed to discontinued.
- 04 Feb 2019 Status changed from recruiting to completed.
- 04 Jan 2019 This trial has been Discontinued in Germany (end date: 2018-09-25)